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Acute uncomplicated cystitisa b s t r a c t
The Japanese Surveillance Committee conducted a second nationwide surveillance of antimicrobial
susceptibility patterns of uropathogens responsible for acute uncomplicated cystitis (AUC) in premen-
opausal patients aged 16e40 years old at 31 hospitals throughout Japan from March 2015 to February
2016. In this study, the susceptibility of causative bacteria (Escherichia coli, Klebsiella pneumoniae,
Staphylococcus saprophyticus) for various antimicrobial agents was investigated by isolation and culturing
of organisms obtained from urine samples. In total, 324 strains were isolated from 361 patients, including
E. coli (n ¼ 220, 67.9%), S. saprophyticus (n ¼ 36, 11.1%), and K. pneumoniae (n ¼ 7, 2.2%). The minimum
inhibitory concentrations (MICs) of 20 antibacterial agents for these strains were determined according
to the Clinical and Laboratory Standards Institute (CLSI) manual. At least 93% of the E. coli isolates showed
susceptibility to fluoroquinolones and cephalosporins, whereas 100% of the S. saprophyticus isolates
showed susceptibility to fluoroquinolones and aminoglycosides. The proportions of fluoroquinolone-
resistant and extended-spectrum b-lactamase (ESBL)-producing E. coli strains were 6.4% (13/220) and
4.1% (9/220), respectively. The antimicrobial susceptibility of K. pneumoniae was retained during the
surveillance period, while no multidrug-resistant strains were identified.
In summary, antimicrobial susceptibility results of our second nationwide surveillance did not differ
significantly from those of the first surveillance. Especially the numbers of fluoroquinolone-resistant and
ESBL-producing E. coli strains were not increased in premenopausal patients with AUC in Japan.
© 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases.
Published by Elsevier Ltd. All rights reserved.1. Introduction
An uncomplicated urinary tract infection (UTI) is one of the
most common diseases caused by bacteria encountered in outpa-
tient settings. Acute uncomplicated cystitis (AUC) accounts for the
greatest number of uncomplicated UTI cases, particularly among
young sexually active individuals [1]. The condition is diagnosed
and treated by physicians of various types, including urologists and
gynecologists, as well as other medical and health care providers
[2]. Although AUC should be treated with an effective antimicrobial
agent, management of AUC patients has recently become more
difficult, because of increasing bacterial resistance to antimicrobial
agents in case of uncomplicated UTI [34], increasing the importance
of more appropriate and effective antimicrobial agents to control
AUC.
Several studies throughout the world have reported increased
isolation of fluoroquinolone-resistant or extended-spectrum b-
lactamase (ESBL)-producing gram-negative bacilli in patients withAUC [5e8]. Therefore, awareness of a specific regional resistance
ratio is important prior to initiation of empiric antimicrobial ther-
apy for treatment of AUC. In order to comprehensively investigate
antimicrobial susceptibility and resistance of bacterial urinary
pathogens, the Japanese Society of Chemotherapy (JSC), Japanese
Association for Infectious Diseases (JAID) and Japanese Society for
Clinical Microbiology (JSCM) established the Japanese Surveillance
Committee in 2008. The first survey conducted in Japan of the
antimicrobial susceptibility patterns of the uropathogens Escher-
ichia coli and Staphylococcus saprophyticus, responsible for female
AUC, was conducted during the period from April 2009 to
November 2010 [4]. Information regarding the antimicrobial sus-
ceptibility of pathogens isolated from AUC patients is of particular
value, as that is reflected in guidelines presented for treatment. The
second nationwide surveillance of AUC pathogens was conducted
during the period from March 2015 to February 2016, with Klebsi-
ella pneumoniae added to E. coli and S. saprophyticus for surveillance
of multidrug-resistant pathogens over time.
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2.1. Japanese Surveillance Committee
The Japanese Surveillance Committee, consisting of the JSC, JAID
and JSCM, conducted a second nationwide surveillance of antimi-
crobial susceptibility patterns of uropathogens responsible for fe-
male AUC. The study protocol was prepared by the working group
and accepted by the governing board of the committee. Ethics
approval was obtained from the ethical committee of each facility
or from the ethical committee of a specific non-profit organization,
CREC net, located in Kitakyushu, Japan. The clinicians who partic-
ipated in this study explained its purpose to their patients orally or
through written documents, and obtained written consent for
participation. All results were included in the study database, with
patient information remaining anonymous.2.2. Patients
Among the patients with AUC who visited any of 31 related
institutions across Japan (Table 1) from March 2015 to February
2016, those with symptoms such as micturition pain, frequent
urination, urgency, or suprapubic pain, and who met the following
inclusion criteria were enrolled.
The inclusion criteria were set in accordance with the Japanese
guidelines for clinical research of antimicrobial agents developed
for urogenital infections, first edition [9]. Patients with AUC were
required to be female, aged 16e40 years old, without underlying
urinary tract disease and/or factors contributing to onset, wors-
ening, or prolongation of urinary tract infection, and without dia-
betes mellitus, malignancy receiving treatment, cerebrovascular
disease requiring assistance, or presently undergoing corticosteroid
or immunosuppressant therapy. One or more of the following was
also required: pyuria confirmed by a reagent strip; 5 white bloodTable 1
Participating Japanese medical institutions.
Nissin Urological Clinic, Hokkaido
Tomakomai Urology and Cardiology Clinic, Hokkaido
iClinic, Miyagi
Tsujinaka Hospital Kashiwanoha, Chiba
Hosobe Clinic, Tokyo
Department of Urology, Fuji City Genaral Hospital, Shizuoka
Takeuchi Urology and Dermatology Clinic, Gifu
Izumitani Fureai Clinic, Aichi
Narita Clinic, Aichi
Yoh Urology and Dermatology Clinic, Aichi
Department of Urology, Tane General Hospital, Osaka
Department of Urology, Saiseikai Chuwa Hospital, Nara
Takashima Urology Clinic, Nara
Cyokyu Tenma Clinic, Hyogo
Ihara Clinic, Hyogo
Matsumura Urology Clinic, Hyogo
Yoshioka Urology Clinic, Hyogo
Araki Urological Clinic, Okayama
Hirajima Clinic, Okayama
Kadena Urological Clinic, Hiroshima
Shirane Urology Clinic, Hiroshima
Sumii Clinic, Hiroshima
Ito Urology Clinic, Fukuoka
Kawai Urology Clinic, Fukuoka
Nishi Urology and dermatology Clinic, Fukuoka
Nishimura Urology Clinic, Fukuoka
Remedy Kitakyushu Nephro Clinic, Fukuoka
Kagoshima Prefectural Ohshima Hospital, Kagoshima
Kawahara Urology Clinic, Kagoshima
Makinose Urological Clinic, Kagoshima
Ootemachi Clinic, Kagoshima
Listed in alphabetical order, location noted by prefecture.cells (WBCs) per high-power field (hpf) in a microscopy examina-
tion of urine sediment, or 10 WBCs/mm3 measured by flow
cytometry or a counting chamber; and bacteriuria shown
by  103 colony-forming units (cfu)/ml (for midstream urine,
104 cfu/ml).2.3. Bacteriological examination
2.3.1. Collection of urine samples and bacterial strains
Urine samples were collected from patients with AUC as
midstream urine or via a catheter in accordance with the Japanese
guideline for clinical research of antimicrobial agents on urogenital
infections, first edition [9]. They were examined using a Slide Cul-
ture U® system (Eiken Chemical Co. Ltd., Tokyo, Japan) by the in-
vestigators and then sent on the same day to a central
bacteriological laboratory (Infection Control Research Center,
Kitasato Institute for Life Science, Kitasato University, Tokyo, Japan)
for testing. If the same patient participated a second time in the
study, a duplicate specimen was not used.
Bacterial strains thus obtained were cultured at 35 ± 2 C for
16e24 h, then isolates were identified, counted, and stored
at 80 C for future examination.2.3.2. Susceptibility testing and determination of minimal
inhibitory concentration (MIC)
The MICs of antimicrobial agents used against the 3 main
causative organisms of AUC examined, E. coli, K. pneumoniae, and
S. saprophyticus, were determined using a broth microdilution
method according to the guidelines of the Clinical and Laboratory
Standards Institute (CLSI) set out in standards M7-A7 [10], M100-
S17 [11], and M45-A [12], respectively, using cation-adjusted
Mueller-Hinton broth (25 mg/l Caþþ and 12.5 mg/l Mgþþ; CA-MH
broth). Bacterial cells were grown overnight, adjusted to approxi-
mately 104 cfu/well (105 cfu/ml) and incubated at 35±2 C for
16e20 h.2.3.3. Quality control
The accuracy of determination of the MICs of the antimicrobial
agents was determined according to the recommendations of the
CLSI, using the following control strains: E. coli ATCC25922 for
E. coli and K. pneumoniae, and S. aureus ATCC29213 for
S. saprophyticus. Furthermore, E. coli ATCC35218 was utilized as a
control strain for MIC determination of b-lactam antibiotics used in
combination with b-lactamase inhibitors.2.3.4. Antibacterial agents
Susceptibility of the E. coli strains for the following 17 antimi-
crobial agents were tested: ampicillin (ABPC); 1 penicillin in com-
bination with b-lactamase inhibitors, clavulanic acid-amoxicillin
(CVA/AMPC); 5 oral cephalosporins, cefaclor (CCL), cefpodoxime
(CPDX), cefdinir (CFDN), cefditoren (CDTR), and cefcapene (CFPN);
1 penem, faropenem (FRPM); 2 aminoglycosides, gentamicin (GM),
and amikacin (AMK); 4 fluoroquinolones, ciprofloxacin (CPFX),
levofloxacin (LVFX), tosufloxacin (TFLX), and sitafloxacin (STFX);
and 3 others, fosfomycin (FOM), sulfamethoxazole/trimethoprim
(ST) and nitrofurantoin (NIT).
Additionally, the susceptibilities of K. pneumoniae strains was
tested with 16 antimicrobial agents in the same manner as the
E. coli testing, except for NIT.
The susceptibility of S. saprophyticus strains was tested with 19
antimicrobial agents in the same manner as with E. coli testing,
except for NIT, with oxacillin (MPIPC); and 2 glycopeptides, van-
comycin (VCM) and teicoplanin (TEIC), added.
Table 2
Patient background information.
Total number of
urine samples
Number of
analyzed urine
samples
N (%) N (%)
Gender
female 402 99.8 361 100
male 1 0.2
Age, years
16-19 21 5.2 21 5.8
20-29 164 40.7 164 45.4
30-39 164 40.7 164 45.4
40-49 23 5.7 12 3.3
50-59 8 2.0 e e
60- 23 5.7
Collection method
catheter 4 1.0 3 0.8
midstream urine 399 99.0 358 99.2
Menopausal status
premenopausal 372 92.3 361 100
postmenopausal 30 7.4 e e
male 1 0.2 e e
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A Cica-Beta Test (Kanto Chemical, Tokyo, Japan), a rapid method
for detection of extended-spectrum b-lactamase (ESBL) -producing
E. coli and K. pneumoniae, was used by directly scraping a colony
and applying it to the disk [13,14]. A modified Hodge Test, a method
for detection of carbapenemase-producing Gram-negative bacilli,
was used for detection of Klebsiella pneumoniae carbapenemase
(KPC) -producing K. pneumoniae. These tests were conducted ac-
cording to the reference manual supplied by the manufacturer.
2.4. Patient characteristics
On the day of urine collection, each patient was interviewed by
an investigator and the following characteristics were noted: age,
menopausal status, and method used for urine sample collection.
Patient clinical findings and identified bacterial species were
recorded with a standardized data sheet. Microbiological data ob-
tained were analyzed according to the patient clinical settings and
profile.
2.5. Assessment
2.5.1. Assessment of antimicrobial susceptibility
The antimicrobial susceptibility of the pathogens was catego-
rized into 1 of 3 classes; namely, susceptible, intermediate, or
resistant, according to the MIC breakpoints recommended by CLSI
standards M100-S26 [15], and susceptibility rate was defined as the
percentage of susceptible strains. For agents not described in the
CLSI guidelines, breakpoints were set based on those for similar
agents. The breakpoints for LVFX in the CLSI guidelines are 2 mg/
ml (susceptible), 4 mg/ml (intermediate), and 8 mg/ml (resistant),
and those for CPFX are 1, 2, and 4 mg/ml, respectively. Thus, the
corresponding values for TFLX and STFXwere likewise set at1 mg/
ml (susceptible), 2 mg/ml (intermediate), and 4 mg/ml (resistant).
The breakpoints for CPDX in the CLSI guidelines are 2 mg/ml
(susceptible), 4 mg/ml (intermediate), and 8 mg/ml (resistant), and
those for CFDN are 1, 2, and 4 mg/ml, respectively. Thus, the
corresponding values for CDTR, CFPN, and FRPM were set at 1 mg/
ml (susceptible), 2 mg/ml (intermediate), and 4 mg/ml (resistant).
Fluoroquinolone resistance was defined as that equivalent to the
MIC of LVFX for E. coli (4 mg/ml).
2.5.2. Assessment of antimicrobial resistant rate of E. coli by
isolated age
The antimicrobial resistant rate of E. coli was statistically
compared between the results of the first nationwide survey [3]
and those of the present surveillance using a chi-square test for
independence. A P-value of <0.05 was considered to indicate sta-
tistical significance. For that comparison, data obtained in the first
nationwide survey were sub-analyzed after dividing the patients
into 2 groups, 16 to 40 and over 40 years old.
3. Results
3.1. Study population and patient characteristics
A total of 403 urine obtained from 31 hospitals in Japan during
the study period were registered, among which 361 were included
in the analysis. Forty-two samples obtained from thirty post-
menopausal patients, eleven patients above 40 years old, and one
male patient, were excluded. Patient background information is
shown in Table 2. All patients with AUC were female and pre-
menopausal, and the mean age (±standard deviation) was
28.9 ± 6.4 years. Nearly all of the urine samples (99.0%) were
collected as midstream urine.3.2. Causative bacteria
Causative bacteria in the patient cohort are shown in Table 3.
The number of strains isolated as causative from 361 patients
with AUC was 324. Major causative bacteria included 220 E. coli
(67.9%), 36 S. saprophyticus (11.1%), 7 K. pneumoniae (2.2%), 16
Streptococcus agalactiae (4.9%), 11 Staphylococcus epidermidis
(3.4%), and 10 Enterococcus faecalis (3.1%) organisms. Gram-
negative and -positive bacteria accounted for 72.8% (236
strains) and 27.2% (88 strains), respectively, of all identified
strains, for a ratio of 7:3.
3.2.1. Susceptibility profile
MIC distribution, i.e. MICs for 50% and 90% of the organisms
(MIC50 and MIC90 values, respectively), is shown in Tables 4e7. The
susceptibility rate based on theMIC breakpoints set by CLSI for each
antimicrobial agent were stratified by E. coli, ESBL-producing E. coli,
K. pneumoniae, and S. saprophyticus, and are shown in Figs. 1e4,
respectively.
3.2.2. Antimicrobial susceptibility of Escherichia coli (220 strains)
The susceptibility rates of 220 E. coli strains isolated from the
premenopausal female patients with AUC for oral cephalosporins
were high (92.3% for CCL, 92.3% for CPDX, 92.7% for CFDN, 92.7% for
CDTR, 94.5% for CFPN), with CFPN showing the highest rate (Fig. 1).
The MIC90 of a penicillin derivative (ABPC) for these E. coli strains
was 256 mg/ml, whereas the MIC90 of a penicillin derivative in the
presence ofb-lactamase inhibitors (CVA/AMPC) was decreased to
16 mg/ml (Table 4). The MIC90 of 5 oral cephalosporins and 1 oral
penem (FRPM) ranged from 0.5 to 4 mg/ml, thus each was found to
be active against E. coli (Table 4). The susceptibility rates for all
fluoroquinolones were also high (93.6% for LVFX, 99.5% for STFX,
93.6% for CPFX, 93.6% for TFLX), with STFX showing the highest rate
(Fig. 1). The MIC90 of 5 fluoroquinolones for these E. coli strains
ranged from 1 to32 mg/mL and the percentage of resistant strains
was 6.4%. Susceptibility to 2 aminoglycosides, GM and AMK, was
very highwith rates of 95.0% and 100%, respectively, while FOM and
NIT also showed very high rates of 100% and 99.5%, respectively
(Fig. 1).
Nine ESBL-producing strains were detected (9/220; 4.1%). For
those strains, the MIC90 of ABPC and 5 oral cephalosporins ranged
Table 3
Causative organisms isolated from patients with acute uncomplicated cystitis (AUC).
Organisms N (%)
Gram-negative bacteria 236 72.8
Escherichia coli 220 67.9
Klebsiella pneumoniae 7 2.2
Citrobacter koseri 4 1.2
Proteus mirabilis 4 1.2
Enterobacter aerogenes 1 0.3
Gram-positive bacteria 88 27.2
Staphylococcus saprophyticus 36 11.1
Streptococcus agalactiae 16 4.9
Staphylococcus epidermidis 11 3.4
Enterococcus faecalis 10 3.1
Staphylococcus aureus 6 1.9
Staphylococcus sp. 4 1.2
Streptococcus anginosus 3 0.9
Staphylococcus caprae 1 0.3
Enterococcus faecium 1 0.3
H. Hayami et al. / J Infect Chemother 25 (2019) 413e422 417from 32 to 256 mg/ml (Table 5), and the susceptibility rate for all
antimicrobials was decreased, except for FRPM, AMK, STFX, FOM,
and NIT. Remarkably,100% of the examined strains were resistant to
ABPC, CCL, CPDX, and CDTR (Fig. 2).Table 4
Distribution of minimal inhibitory concentrations (MICs) for Escherichia coli (n ¼ 220).
Antibacterial agent M I C (mg/mL)
&0.06 0.125 0.25 0.5 1 2 4 8 16
Ampicillin 2 63 89 5
Clavulanic acid-amoxicillin 7 53 98 23 28
Cefaclor 40 107 39 16 1
Cefpodoxime 1 114 83 4 1 2 3 2
Cefdinir 5 123 61 14 1 1 2 2 1
Cefditorena 3 104 92 4 1 4 3 1
Cefcapenea 18 120 61 8 3 2 1 4
Faropenema 45 156 15 2 1 1
Gentamicin 6 175 26 2 3
Amikacin 38 143 36 3
Ciprofloxacin 172 2 25 4 3 1 4 2
Levofloxacin 167 4 7 23 5 5 2 7
Tosufloxacina 173 18 10 4 1 1 1
Sitafloxacina 197 9 6 7 1
Fosfomycin 3 53 86 50 14 3 1 3
Sulfamethoxazole/trimethoprim 147 33 7 9 1 23**
* S128, ** S32, *** S16.
a Agents not described in the CLSI guidelines.
Table 5
Distribution of minimal inhibitory concentrations (MICs) for ESBL-producing Escherichia
Antibacterial agent M I C (mg/mL)
&0.06 0.125 0.25 0.5 1 2 4 8 16
Ampicillin
Clavulanic acid-amoxicillin 4 4
Cefaclor
Cefpodoxime 1
Cefdinir 1
Cefditorena 1
Cefcapenea 1 1 4
Faropenema 5 4
Gentamicin 4 1
Amikacin 1 6 2
Ciprofloxacin 3 2 1
Levofloxacin 2 1 2 1 3
Tosufloxacina 3 1 1 1
Sitafloxacina 5 1 1 2
Fosfomycin 4 3 2
Sulfamethoxazole/trimethoprim 3 2 1 3***
* S128, ** S32, *** S16.
a Agents not described in the CLSI guidelines.3.2.3. Antimicrobial susceptibility of Klebsiella pneumoniae
(7 strains)
The susceptibility rate of 7 K. pneumoniae strains isolated from
the premenopausal female patients with AUC for the penicillin
derivative with the b-lactamase inhibitors, 5 oral cephalosporins,
and the oral penem was high (85.7% for CVA/AMPC, CCL, CPDX,
CFDN, CDTR, CFPN, FRPM) (Fig. 3). Therefore, all were considered
active against K. pneumoniae (Table 6). The susceptibility rate for all
fluoroquinolones was also high (100% for LVFX, STFX, CPFX, TFLX)
(Fig. 3). The MIC90 for the fluoroquinolones with these
K. pneumoniae strains ranged from 0.25 to 1 mg/mL and there no
resistant strains (0%) were identified. Susceptibility to 2 amino-
glycosides (GM, AMK) and FOM was very high at 100%. FOM was
also very high with susceptibility rates of 100% (Fig. 3). No ESBL- or
KPC-producing strain (0/7; 0.0%) was detected.3.2.4. Antimicrobial susceptibility of Staphylococcus saprophyticus
(36 strains)
The 36 S. saprophyticus strains isolated from the premenopausal
female patients with AUC showed variable susceptibility to oral b-
lactam antibiotics. The MIC90 of 3 penicillin derivatives (MPIPC,
ABPC, CVA/AMPC) ranged from 0.5 mg/ml, and that of 5 oralBreakpoint MIC (mg/mL)
32 64 128 S256 MIC50 MIC90 Susceptible Intermediate Resistant
3 2 56 4 S256 &8 16 S32
3 5 3* 4 16 &8 16 S32
1 4 2 10 1 4 &8 16 S32
2 3 4 1 0.25 0.5 &2 4 S8
1 3 6* 0.125 0.5 &1 2 S4
8* 0.25 0.25
3 0.25 0.5
0.5 0.5
1 2 4 1 0.5 1 &4 8 S16
2 4 &16 32 S64
4 3 &0.06 0.25 &1 2 S4
&0.06 0.5 &2 4 S8
12** &0.06 0.25
&0.06 0.125
5 2 0.5 2 &64 128 S256
* 0.06 S16 &2 S4
coli (n ¼ 9).
Breakpoint MIC (mg/mL)
32 64 128 S256 MIC50 MIC90 Susceptible Intermediate Resistant
9 S256 S256 &8 16 S32
1 16 32 &8 16 S32
1 8 S256 S256 &8 16 S32
1 2 4 1 128 S256 &2 4 S8
3 5* 128 128 &1 2 S4
8* 128 128
3 16 32
0.5 1
1 2 1 16 S256 &4 8 S16
2 4 &16 32 S64
2 1 0.25 64 &1 2 S4
0.5 16 &2 4 S8
3** 0.25 32
&0.06 1
1 16 &64 128 S256
0.125 S16 &2 S4
Table 6
Distribution of minimal inhibitory concentrations (MICs) for Klebsiella pneumoniae (n ¼ 7).
Antibacterial agent M I C (mg/mL) Breakpoint MIC (mg/mL)
&0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 S256 MIC50 MIC90 Susceptible Intermediate Resistant
Ampicillin 4 2 1 32 S256 &8 16 S32
Clavulanic acid-amoxicillin 6 1* 2 S128 &8 16 S32
Cefaclor 5 1 1 0.5 S256 &8 16 S32
Cefpodoxime 6 1 0.125 16 &2 4 S8
Cefdinir 4 1 1 1 &0.06 32 &1 2 S4
Cefditorena 3 3 1 0.25 2
Cefcapenea 3 3 1 0.5 4
Faropenema 2 4 1 0.5 4
Gentamicin 5 2 0.25 0.5 &4 8 S16
Amikacin 7 1 1 &16 32 S64
Ciprofloxacin 6 1 &0.06 0.5 &1 2 S4
Levofloxacin 4 2 1 &0.06 1 &2 4 S8
Tosufloxacina 6 1 &0.06 0.5
Sitafloxacina 6 1 &0.06 0.5
Fosfomycin 2 4 1 8 16 &64 128 S256
Sulfamethoxazole/trimethoprim 2 4 1 0.25 2 &2 S4
* S128.
a Agents not described in the CLSI guidelines.
Table 7
Distribution of minimal inhibitory concentrations (MICs) for Staphylococcus saprophyticus (n ¼ 36).
Antibacterial agent M I C (mg/mL) Breakpoint MIC (mg/mL)
&0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 128 S256 MIC50 MIC90 Susceptible Intermediate Resistant
Oxacillin 1 30 3 1 1 0.5 1 &0.25 S0.5
Ampicillina 2 29 3 1 1 0.25 0.5
Clavulanic acid-amoxicillin1) 23 11 1 1 0.25 0.5
Cefaclora 1 24 9 1 1 1 2
Cefpodoximea 3 21 10 1 1 2 4
Cefdinira 1 18 15 1 1* 0.125 0.25
Cefditorena 12 21 1 1 1* 1 1
Cefcapenea 1 16 14 3 1 1 1 2
Faropenema 27 7 1 1 0.25 0.5
Gentamicin 33 2 1 &0.06 &0.06 &4 8 S16
Amikacin 13 22 1 0.25 0.25 &16 32 S64
Ciprofloxacin 20 16 0.25 0.5 &1 2 S4
Levofloxacin 36 0.5 0.5 &1 2 S4
Tosufloxacina 18 18 &0.06 0.125
Sitafloxacina 36 &0.06 &0.06
Fosfomycina 5 17 8 6 64 S256
Vancomycin 28 7 1 1 2 &4 8 to 16 S32
Teicoplanin 10 20 5 1 2 4 &8 16 S32
Sulfamethoxazole/trimethoprim 33 3 &0.06 &0.06 &2 S4
* S128.
a Agents not described in the CLSI guidelines.
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Therefore, all were active against S. saprophyticus, except for two
cephalosporins (CPDX and CFPN) (Table 7). The MIC90 of fluo-
roquinolones for S. saprophyticus ranged from 0.06 to 0.5 mg/ml,
while fluoroquinolone resistant strains were not seen (Table 7). All
examined S. saprophyticus strains were susceptible to 2 amino-
glycosides, GM and AMK, and 2 glycopeptides, VCM and TEIC
(Fig. 4). On the other hand the MIC50 and MIC90 values for FOM
were 64 and  256 mg/ml, respectively.3.2.5. Assessment of antimicrobial resistant rate of Escherichia coli
by year of isolation
Data obtained in the first surveillance conducted in 2009e2010
were analyzed in terms of age and compared with those from the
present surveillance, after dividing the patients into 2 sub-groups
aged 16e40 years and over 40 years. In a comparison between
the first and second surveillance for patients aged 16e40 years, the
antimicrobial resistant rates of E. coli to various antimicrobialsincluding fluoroquinolones were not significantly different, except
for CVA/AMPC (P ¼ 0.00388) (Table 8).4. Discussion
It is important to understand the antimicrobial susceptibility
profiles of causative bacteria for AUC in local areas, because the
resistance patterns of such pathogens vary considerably among
regions and countries. Accordingly, we investigated trends over
time regarding the distribution of causative bacteria and their
susceptibility profile in patients with AUC in Japan.
AUC frequently occurs in young sexually active individuals, and
is considered to be uncomplicated when sporadic or a community-
acquired episode in otherwise healthy individuals with no known
structural or functional abnormalities of the genitourinary tract
[16,17]. A previous cohort study showed that the rate of incidence of
AUC is 0.5e0.7 per individual per year among young women [1]. A
diagnosis of AUC can be made with high probability based on a
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Fig. 1. The antimicrobial susceptibility of Escherichia coli was categorized as susceptible, intermediate, or resistant, according to the MIC breakpoints recommended by the CLSI
standards M100-S26. Sixteen antimicrobial agents were tested with 220 strains of E. coli.
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Fig. 2. The antimicrobial susceptibility of ESBL-producing Escherichia coliwas categorized as susceptible, intermediate, or resistant, according to the MIC breakpoints recommended
by the CLSI standards M100-S26. Sixteen antimicrobial agents were tested with 9 strains of ESBL-producing E. coli.
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Fig. 3. The antimicrobial susceptibility of Klebsiella pneumoniae was categorized as susceptible, intermediate, or resistant, according to the MIC breakpoints recommended by the
CLSI standards M100-S26. Sixteen antimicrobial agents were tested with 7 strains of K. pneumoniae.
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Fig. 4. The antimicrobial susceptibility of Staphylococcus saprophyticuswas categorized as susceptible, intermediate, or resistant, according to the MIC breakpoints recommended by
the CLSI standards M100-S26. Nineteen antimicrobial agents were tested with 36 strains of S. saprophyticus.
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urinalysis and urine culture results in women younger than 40
years old [18]. On the other hand, symptomatic women aged over
40 years may potentially have an underlying disease of the urinary
tract. Since the symptoms of AUC can be mimicked by those of
interstitial cystitis, urethral syndrome, and bladder carcinoma,
symptomatic patients older than 40 years should be evaluated for a
noninfectious cause related to their condition [19]. Postmenopausal
women presentedwith lower urinary tract symptoms are less likely
to be cured by antibiotics, particularly short courses of therapy, as
compared to premenopausal women [20], thus it is important for
physicians to differentiate between uncomplicated and compli-
cated UTI, though the definitions are not equivocal. In order to
clarity factors related to a diagnosis of AUC, we conducted the
present surveillance in premenopausal women aged 16e40 years
old.
The microbial etiology of AUC is regarded to be well established
and reasonably consistent. E. coli has been reported to be the
pathogen isolated most frequently during episodes of AUC,Table 8
Stratified analysis of antimicrobial resistant rate of E. coli by year of isolation.
Antibacterial agent Resistant rate (%) p value
Year 2009e10 2015e16
Patient age, years 16e40 16e40
Number of patients 113 220
Ampicillin 23.0 27.7 NS
Clavulanic acid-amoxicillin 6.2 17.7 0.00388
Cefaclor 6.2 7.7 NS
Cefpodoxime 5.3 7.7 NS
Cefdinir 4.4 7.3 NS
Cefditoren 2.7 7.3 NS
Cefcapene 3.5 5.9 NS
Faropenem 1.8 1.8 NS
Gentamicin 3.5 5.0 NS
Amikacin 0.0 0.0
Ciprofloxacin 8.0 6.4 NS
Levofloxacin 8.0 6.4 NS
Tosufloxacin 8.0 6.4 NS
Sitafloxacin 0.0 0.5 NS
Fosfomycin 0.0 0.0
Sulfamethoxazole/trimethoprim 9.7 10.5 NS
NS: P value > 0.05.followed by S. saprophyticus [19,21], while other pathogens, such as
K. pneumoniae, Proteus mirabilis, and Enterococcus faecalis, are oc-
casionally involved [3,6,21]. In the present study, E. coli organisms
comprised the largest number (220 of 324; 67.9%) of isolates and
the distribution of causative bacteria for AUC was similar to that in
mega-surveillance studies conducted in other countries [6,22,23].
As compared with the first nationwide surveillance in Japan [4], the
isolation rate of S. saprophyticus in patients aged 16e40 years old
(sub-analysis) was slightly high in the present study (11.1% vs. 9.4%),
indicating that AUC caused by S. saprophyticus is showing an
increasing trend in premenopausal women in Japan.
Fluoroquinolone-resistant E. coli has been noted to be a world-
wide clinical problem. However, in the present study, the propor-
tion of fluoroquinolone-resistant or intermediate E. coli isolated
from patients with AUC was 6.4%, slightly lower than the rates
noted in our other recent studies (8.2e12.3%) [3,4]. When sub-
analysis according to age was performed for the antimicrobial
susceptibility of E. coli in patients aged 16e40 years old who
participated in the first nationwide surveillance in Japan, the sus-
ceptibility rates for CCL, CPDX, CFPN, CPFX, and LVFX were 93.8%,
94.7%, 96.5%, 92.0%, and 92.0%, respectively. In addition, the present
study showed similar results in terms of susceptibility for cepha-
losporins as well as fluoroquinolones. While susceptibility to STFX
was extremely high (99.5%), the susceptibility rate of E. coli isolated
from AUC cases towards conventional fluoroquinolones was 93.6%,
similar to the rates for oral cephalosporins (92.3e94.1%). On the
other hand, E. coli showed high rates of susceptibility to FRPM and
FOM at 98.2% and 100%, respectively. In the present study, 9 ESBL-
producing E. coli (4.1%) isolates were identified, which is an isola-
tion rate approximately 4 times higher than previous Japanese
findings presented in 2003 [24], though that rate did not show an
increasing trend for females aged 16e40 years old as compared to
the first surveillance conducted from 2009 to 2010 [4]. Among the
ESBL-producing E. coli isolates, susceptibility to ABPC, CCL, CPDX,
CFDN, CDTR, and CFPN was 0%, whereas that to FRPM, AMK, STFX,
FOM, and NIT was 100%. Together, these results indicate that the
antimicrobial resistant rates of E. coli organisms isolated from
premenopausal patients with AUC in Japan have not increased in
the most recent 5-year period. Nevertheless, the rate of resistance
to CVA/AMPC was significantly increased in the present study,
suggesting the necessity to continue surveillance, since that is
considered to be a clinically effective agent for treating patients
infected with ESBL-producing E. coli [25].
H. Hayami et al. / J Infect Chemother 25 (2019) 413e422 421K. pneumoniae is commonly isolated from UTI cases, as well as
patients with respiratory tract, surgical site, bacteremia, and other
types of infection. Recently, antimicrobial-resistant K. pneumoniae
strains have emerged and reported to be spreading throughout the
world [26e28]. In the samples obtained in the present study from
premenopausal women with AUC, only 7 of the K. pneumoniae
strains isolated (2.2%) were found to not show multidrug-
resistance, while neither ESBL- nor KPC-producing strains were
isolated.
Based on the reported detection rate of pathogens by meno-
pausal status, AUC caused by S. saprophyticus is significantly more
common in premenopausal women [4]. In addition, the
S. saprophyticus strains isolated in the present investigation were
found have a high susceptibility to fluoroquinolones and amino-
glycoside antibiotics, as compared to other b-lactams and FOM. On
the other hand, both E. coli and S. saprophyticus showed a rate of
resistance to ampicillin (ABPC) of about 30%, thus that drug should
no longer be recommended for empiric therapy for AUC as a single
agent without a b-lactamase inhibitor [4,6].
According to the Guidelines for Antimicrobial Use published
by JAID and JSC in 2015 [29], the standard antimicrobial regimen
for treatment of AUC in premenopausal women is 3 days of
therapy with fluoroquinolones or 5e7 days with b-lactam anti-
biotics. When Gram-positive cocci are suspected or have been
detected, 3 days of therapy with fluoroquinolones is recom-
mended for both pre- and postmenopausal women. The results
of the present second surveillance in Japan suggest the aptness
of such empirical treatment. Fluoroquinolones are most effective
against Gram-positive cocci in terms of antimicrobial effect. On
the other hand, use of fluoroquinolones was associated with
collagen-related disorders [30] and an increased risk of aortic
aneurysm and dissection [31]. Physicians should be aware of
this possible drug safety risk associated with fluoroquinolone
therapy. In addition, in order to suppress induction of fluo-
roquinolone resistance, physicians should refrain from using
fluoroquinolones as routines for elderly women at post-
menopausal status with AUC caused by Gram-positive cocci and
alternatively consider taking AMPC/CVA. Thus, for appropriate
selection of an antimicrobial agent, it is important for the
treating physician to distinguish causative pathogens of AUC
between coccus- and coli-forms. For that, microscopy findings of
urine sediment with or without Gram staining is recommended,
not only to ensure diagnostic accuracy, but also to distinguish
between those forms. In the future, flow cytometry may take the
place of microscopy, because a system for discriminating be-
tween Gram-positive and negative bacteria has been developed
and may be available soon for clinical use [32].
5. Conclusions
AUC is of significant importance in the community due to its
high prevalence, particularly among young sexually active women.
To appropriately use antimicrobial agents for empiric therapy, it is
important to confirm the susceptibility profile of the causative
bacterium prior to treatment and also carefully consider patient
characteristics. Regarding the premenopausal group, antimicrobial
susceptibility results of our second nationwide surveillance did not
differ significantly from those of the first surveillance, which was
conducted 5 years earlier, though antimicrobial resistant gram-
negative bacilli have increased in AUC patients throughout the
world. Especially the numbers of fluoroquinolone-resistant and
ESBL-producing E. coli strains were not increased in Japan. The
results presented in this study provide important information for
proper treatment of UTIs and can be a useful reference for future
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